Premium
High‐performance liquid chromatographic analysis of MTX, 7‐OH‐MTX and MTX derivatives: Application to intracellular metabolism in tumor cells (HT 29)
Author(s) -
Durand R.,
Fabre G.,
Cano J. P.,
Catalin J.,
Ahmed O. Ait,
Just S.
Publication year - 1983
Publication title -
journal of applied toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.784
H-Index - 87
eISSN - 1099-1263
pISSN - 0260-437X
DOI - 10.1002/jat.2550030406
Subject(s) - chemistry , high performance liquid chromatography , antifolate , methotrexate , chromatography , metabolism , antimetabolite , intracellular , toxicity , biochemistry , organic chemistry , immunology , biology
In order to study the intracellular metabolism of Methotrexate (MTX) and the cytotoxicity of the antifolates, a specific paired‐ion HPLC method has been developed which permits the simultaneous determination of DAMPA, MTX, 7‐OH‐MTX, MTX‐G1, MTX‐G2 and MTX‐G3. Cells were incubated with 3 H‐MTX. The MTX metabolites were extracted, purified on SEP‐PAK cartridges and further analysed by high‐performance liquid chromatography (HPLC). The stationary phase was constituted by a C 18 μBondapak and the mobile phase by 5 mM phosphate buffer (pH 7.4) containing 2.5 mM tetrabutylammonium nitrate. The elution was performed with a linear methanol gradient (20–30%). HPLC fractions were collected and radioactivity evaluated by β counting (retention times: DAMPA = 12.93 min; MTX = 18.29 min; 7‐OH‐MTX = 21.13 min; MTX‐G1 = 22.69 min; MTX‐G2 = 26.81 min; MTX‐G3 = 30.61 min). This analytical procedure was applied to separate and characterize multiple forms of MTX polyglutamate derivatives in HT 29, a human adenocarcinoma cell line varying the incubation time (4–18 h) and MTX concentration (0.6‐10.6 μM). The incorporation process seems to be characteristic of a cell line resistant to MTX. The incorporation were very low and after a 4‐h exposure time only 5% of the MTX was converted to polyglutamates. Between 1.6 and 10.6 μM MTX, no difference was observed in the polyglutamization. The defect in the incorporation of the drug and in the metabolization process in vitro could partially explain the failure of the MTX treatment in colorectal cancer.